EMA Recommends Granting a Marketing Authorisation for Nirogacestat By Ogkologos - July 3, 2025 345 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adult patients with progressing desmoid tumours Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at Work as a Key Step towards Protecting the Cancer Workforce and Ensuring High-Quality... MOST POPULAR Study Says Exercise Combats Side Effects of Chemo and Other Meds... July 7, 2021 Dad Gets Tattoo On His Chest To Match Daughter’s Scar So... February 13, 2022 Genetic Risk Score Increases Prediction of Severe Obesity in Adult Survivors... August 5, 2022 EMA Recommends Granting a Marketing Authorisation for Vimseltinib September 5, 2025 Load more HOT NEWS Teen Created App To Help His Non-Verbal Sister And Others Like... First Global Estimates of Cervical Cancer Attributable to HIV New ESMO Framework to Resolve Uncertainties About the De-intensification of Cancer... FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer
